OncLive SOSS

Management of Drug-Induced Interstitial Lung Disease - Episode 6

CDK 4/6 Inhibitors and Identifying ILD in Patients

June 30, 2020

Tiffany A. Traina, MD, Memorial Sloan Kettering Cancer Center, Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center, Axel Grothey, MD, West Cancer Center, University of Tennessee, Jarushka Naidoo, MBBCh, Sidney Kimmel Cancer Center, Johns Hopkins, Tanios Bekaii-Saab, MD, FACP, Mayo Clinic

EP. 1: Antibody Drug Conjugates and Interstitial Lung Disease Risk

EP. 2: Risks for Developing ILD and Personal Experience

EP. 3: Changes in Cancer Treatment and Management of ILD

EP. 4: Use of Antibody Drug Conjugates and Potential for ILD

EP. 5: Rate and Class Effect of ILD with Antibody Drug Conjugates

EP. 6: CDK 4/6 Inhibitors and Identifying ILD in Patients

EP. 7: Managing Patient Symptoms and Clinician Education

EP. 8: Drug-Induced ILD and Rate of Occurrence in GI Cancer Trials

EP. 9: Patient Factors for Developing ILD and Personal Experience

EP. 10: Patient Management upon Developing ILD and Education

EP. 11: Potential Risk of Drug-Induced Interstitial Lung Disease

EP. 12: Personal Experience with Drug-Induced ILD

EP. 13: Rate of ILD and Monitoring Parameters

EP. 14: Identifying Drug-Induced ILD

EP. 15: Patient Management and Educational Tools for ILD

EP. 16: Role of Antibody Drug Conjugates and Personal Experience

EP. 17: Risks for Developing ILD in Gastrointestinal Cancer Studies

EP. 18: Risk of ILD as a Class Effect and Identifying ILD

EP. 19: Changes in Treatment Goals due to Drug Induced ILD

EP. 20: Management of Patients Who Develop ILD

EP. 21: Educational Tools for Possible Drug-Induced ILD